Bridgebio analyst coverage
WebBridgeBio Pharma Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BBIO updated stock price target summary. WebJul 26, 2024 · BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced …
Bridgebio analyst coverage
Did you know?
WebOct 12, 2024 · BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in … WebApr 9, 2024 · On Friday, March 3rd, Neil Kumar sold 120,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $10.96, for a total value of …
WebApr 14, 2024 · BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) gapped up prior to trading on Thursday after SVB Securities raised their price target on the stock from … WebBridgeBio Pharma is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding BridgeBio Pharma's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of BridgeBio …
WebApr 6, 2024 · Analyst Price Forecast Suggests 76.38% Upside As of April 6, 2024, the average one-year price target for BridgeBio Pharma is $26.78. The forecasts range … WebApr 12, 2024 · According to analysts, BridgeBio Pharma's stock has a predicted upside of 53.91% based on their 12-month price targets. What analysts cover BridgeBio Pharma? …
WebMar 17, 2024 · BridgeBio Pharma, Inc. (NASDAQ:BBIO) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The …
WebApr 6, 2024 · BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene,... pims insurance servicesWebBridgeBio Pharma, Inc. (BBIO) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 13.58 +0.74 (+5.76%) At close: 04:00PM EDT. 13.80 +0.22 … pims in quality managementWebApr 6, 2024 · Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they … pinkamena chess 2022WebApr 10, 2024 · NASDAQ:BBIO BridgeBio Pharma - BBIO News Today $13.55 -0.26 (-1.88%) (As of 03/17/2024 12:00 AM ET) Compare Today's Range $13.26 $13.93 50-Day Range $7.45 $18.55 52-Week Range $4.98 $19.94 Volume 7.12 million shs Average Volume 2.88 million shs Market Capitalization $2.05 billion P/E Ratio N/A Dividend Yield … pims is hereWebApr 11, 2024 · BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter. BridgeBio Contact: Vikram Bali … pims investment accountpims islamabad contact numberWebMar 7, 2024 · BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of development programs ranges from early science to … pinkamena and rainbow factory